오리건의 난소암 임상 시험
난소암 관련 연구 37개가 오리건 내 여러 지역에서 참여자를 모집하고 있습니다.
오리건의 도시
공식 연구 텍스트(영어)
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
- Oregon Health and Science University, Portland
피험자 모집 중2/3상
18세 이상 · 모든 성별 · 2026. 11. 13. 업데이트됨 · NCT07001748Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
- Providence Cancer Institute, Portland
피험자 모집 중3상
18세 이상 · 여성 · 2026. 11. 12. 업데이트됨 · NCT06915025Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Providence Newberg Medical Center, Newberg
- Saint Alphonsus Cancer Care Center-Ontario, Ontario
- Providence Willamette Falls Medical Center, Oregon City
- 외 3개
피험자 모집 중2상
전 연령 · 모든 성별 · 2026. 11. 12. 업데이트됨 · NCT05564377A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
- Oncology Associates of Oregon, P.C.(Willamette Valley Cancer Institute) (WVCI) ( Site 8010), Eugene
피험자 모집 중3상
18세 이상 · 여성 · 2026. 11. 10. 업데이트됨 · NCT06824467A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
- Kaiser Permanente Interstate Medical Office - Central ( Site 0089), Portland
피험자 모집 중3상
18세 이상 · 여성 · 2026. 11. 10. 업데이트됨 · NCT07318558Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
- Saint Alphonsus Cancer Care Center-Baker City, Baker City
- Saint Charles Health System, Bend
- Clackamas Radiation Oncology Center, Clackamas
- 외 10개
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 9. 업데이트됨 · NCT06580314A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
- Site 0105, Portland
피험자 모집 중3상
18세 이상 · 여성 · 2026. 11. 9. 업데이트됨 · NCT07546500Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
- Providence Cancer Institute, Portland
피험자 모집 중2상
18세 이상 · 여성 · 2026. 11. 6. 업데이트됨 · NCT06787612A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
- Saint Alphonsus Cancer Care Center-Baker City, Baker City
- Saint Charles Health System, Bend
- Clackamas Radiation Oncology Center, Clackamas
- 외 10개
피험자 모집 중
35세 ~ 50세 · 여성 · 2026. 11. 6. 업데이트됨 · NCT04251052A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)
- Oncology Associates of Oregon, P.C.(Willamette Valley Cancer Institute) (WVCI) ( Site 8000), Eugene
피험자 모집 중3상
18세 이상 · 여성 · 2026. 11. 5. 업데이트됨 · NCT07776691A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- USO - Oncology Associates of Oregon, P. C., Eugene
- Providence Portland Medical Center, Portland
- Kaiser Permanente Interstate Medical Office Central, Portland
- 외 1개
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 4. 업데이트됨 · NCT07213804cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Oregon Health Sciences University, Portland
피험자 모집 중관찰 연구건강한 지원자 환영
40세 이상 · 모든 성별 · 2026. 11. 4. 업데이트됨 · NCT05366881Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- USOR Oncology Associates of Oregon, P.C., Eugene
- Compass Oncology - Rose Quarter, Portland
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 11. 4. 업데이트됨 · NCT05579366Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer
- Compass Oncology - West Cancer Center (Northwest Cancer Specialists, P.C.), Tigard
피험자 모집 중3상
18세 이상 · 여성 · 2026. 11. 4. 업데이트됨 · NCT07564141FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
- Asante Rogue Region al Medical Center, Medford
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 11. 3. 업데이트됨 · NCT06303505A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- Site 0316 - Willamette Valley Cancer Institute/Oncology Associates of Oregon, Eugene
피험자 모집 중2상
18세 이상 · 여성 · 2026. 10. 30. 업데이트됨 · NCT05128825DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
- USA15-0, Portland
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 10. 29. 업데이트됨 · NCT06953089Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
- Legacy Medical Group Gynecologic Oncology, Portland
- Providence Cancer Center Oncology, Portland
피험자 모집 중3상
18세 이상 · 여성 · 2026. 10. 28. 업데이트됨 · NCT06819007A Study of MGC026 in Participants With Advanced Solid Tumors
- Providence Cancer Institute, Portland
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 10. 28. 업데이트됨 · NCT06242470A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- Oncology Associates of Oregon, P.C., Eugene
피험자 모집 중2/3상
18세 이상 · 모든 성별 · 2026. 10. 26. 업데이트됨 · NCT06161025A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- Oregon Health & Science University, Portland
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 10. 22. 업데이트됨 · NCT04657068A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
- Oncology Associates of Oregon, P.C. /ID# 275006, Eugene
- Compass Oncology - West - Tigard /ID# 275101, Tigard
피험자 모집 중2상
18세 이상 · 여성 · 2026. 10. 20. 업데이트됨 · NCT06890338Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- Oncology Associates of Oregon, P.C., Eugene
- Providence Cancer Institute Franz Clinic, Portland
피험자 모집 중3상
18세 이상 · 여성 · 2026. 10. 15. 업데이트됨 · NCT07214779A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
- Willamette Valley Cancer Institute and Research Center /ID# 277714, Eugene
피험자 모집 중2상
18세 이상 · 여성 · 2026. 10. 13. 업데이트됨 · NCT07059845Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Providence Portland Medical Center, Portland
- Providence Cancer Institute (Westside), Portland
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 10. 13. 업데이트됨 · NCT06293898Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
- Research Site, Portland
피험자 모집 중1/2상
18세 ~ 130세 · 모든 성별 · 2026. 10. 5. 업데이트됨 · NCT05797168The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Oregon Health & Science University (OHSU), Portland
피험자 모집 중1/2상
12세 이상 · 모든 성별 · 2026. 10. 2. 업데이트됨 · NCT04585750A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
- Providence Portland Medical Center /ID# 277727, Portland
피험자 모집 중2상
18세 이상 · 여성 · 2026. 10. 1. 업데이트됨 · NCT07024784A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors
- Site 02, Portland
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 9. 30. 업데이트됨 · NCT07814248A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
- Research Site, Portland
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 9. 29. 업데이트됨 · NCT05877599Study of AVZO-021 in Patients With Advanced Solid Tumors
- Avenzo Therapeutics Recruiting Site, Portland
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 9. 28. 업데이트됨 · NCT05867251A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
- Providence Cancer Center Oncology and Hematology Care- Eastside, Portland
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 8. 17. 업데이트됨 · NCT04895709Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
- 517, Eugene
피험자 모집 중2상
18세 이상 · 여성 · 2026. 7. 16. 업데이트됨 · NCT06906341First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- Providence Cancer Institute Franz Clinic, Portland
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 7. 7. 업데이트됨 · NCT05768139A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- Providence Cancer Institute Franz Clinic, Portland
- Providence Oncology and Hematology Care Clinic - Westside, Portland
- Providence St. Vincent Medical Center- Investigational Drug Services, Portland
- 외 1개
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 7. 6. 업데이트됨 · NCT04389632CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
- SCRI - Northwest Cancer Specialists, P.C., Portland
피험자 모집 중2상
18세 이상 · 여성 · 2025. 12. 23. 업데이트됨 · NCT06690775SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Portland
피험자 모집 중관찰 연구
전 연령 · 모든 성별 · 2025. 10. 28. 업데이트됨 · NCT03452774ClinicalTrials.gov 출처, 2026. 11. 15. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.